Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mier

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Biotechnology Therapeutics|January 1, 1993
Leukocyte inhibitory factor (LIF) potentiates human macrophage aggregation and activation responses to calcium ionophore A23187 and directly induces leukotriene B4 and thromboxane A2 releaseP Conti, R C Barbacane, M Reale, et al.
Journal of Clinical Immunology|November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)M Allegretta, M B Atkins, R A Dempsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanomaD F McDermott, J W Mier, D P Lawrence, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant diseaseM B Atkins, J A Gould, M Allegretta, et al.
The Journal of Biological Chemistry|January 8, 2000
Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growthG D Kamphaus, P C Colorado, D J Panka, et al.
The Journal of Cell Biology|June 13, 1998
Calpain regulates actin remodeling during cell spreadingD A Potter, J S Tirnauer, R Janssen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1993
Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humansE V Granowitz, R Porat, J W Mier, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Biotechnology Therapeutics|January 1, 1993
Leukocyte inhibitory factor (LIF) potentiates human macrophage aggregation and activation responses to calcium ionophore A23187 and directly induces leukotriene B4 and thromboxane A2 releaseP Conti, R C Barbacane, M Reale, et al.
Journal of Clinical Immunology|November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)M Allegretta, M B Atkins, R A Dempsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanomaD F McDermott, J W Mier, D P Lawrence, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant diseaseM B Atkins, J A Gould, M Allegretta, et al.
The Journal of Biological Chemistry|January 8, 2000
Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growthG D Kamphaus, P C Colorado, D J Panka, et al.
The Journal of Cell Biology|June 13, 1998
Calpain regulates actin remodeling during cell spreadingD A Potter, J S Tirnauer, R Janssen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1993
Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humansE V Granowitz, R Porat, J W Mier, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Pageof 9